We are scientific pioneers, on a journey to cure cancer and infectious disease
Curious how our Accum™ Technology has 10x the impact on infected cells vs. other approved solutions?
News & Media
Defence Therapeutics Speaks on its Vaccine Development
Defence Therapeutics announces clinical trials for 2023
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthrough in Biotechnology
Vancouver, BC, Canada, July 4, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with...
Defence Patent Portfolio at the Forefront of Success
Vancouver, BC, Canada, June 28, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is the...
Defence Manufacturing of Accutox™ CGMP Final Drug Product Optimization for its Phase I Clinical Trial at City of Hope
Vancouver, BC, Canada, June 16th 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached the...
Innovating Pathways
to Success
Current treatments for cancer and infectious diseases aren’t working. Too many people are dying in search of effective treatments for improved health.
Leading the way with targeted science, strategic products and bold curiosity, Defence Therapeutics are proudly uncovering micro and macro level methods for bringing catalytic change to future patients. How?
Accum™ Technology
A scalable delivery platform with enormous mulitplier effect offering a diversified investment opportunity. Currently supported with our two major programs:
See Accum™ Technology in action
DRUG THE
UNDRUGGABLE®
- Accum™ empowers vaccine development to become entirely scalable across multiple indications.
- This patented platform technology is supporting Defence Therapeutics vaccine development priorities:
- Various cancers
- Infectious diseases
- With drug delivery enhanced by 10x over current solutions (ADC’s), our Accum™ platform is the perfect partner for current and future drug treatments.
- Accum™ is a global solution, and when paired with effective vaccines has the potential to become the therapeutic standard for human diseases.
First-of-its-kind breakthrough, offering precision and efficient cell nucleus drug delivery.
Proprietary and scalable technology targeted at viruses and infectious disease.
Problem-driven solutions confirming strong market potential and upside.
Fully owned assets to be capitalized via global licensing deals.
Exponential scaling potential through partner collaborations.
Proven ability as showcased via flourishing partner pubco’s: world-class and award-winning researchers, University level facilities, a leading global health care system and a sophisticated investor community.
Aggressive, accelerated growth model with two innovative and proprietary pathways to market.
First-of-its-kind breakthrough, offering precision and efficient cell nucleus drug delivery.
Proprietary and scalable technology targeted at viruses and infectious disease.
Problem-driven solutions confirming strong market potential and upside.
Fully owned assets to be capitalized via global licensing deals.
Exponential scaling potential through partner collaborations.
Proven ability as showcased via flourishing partner pubco’s: world-class and award-winning researchers, University level facilities, a leading global health care system and a sophisticated investor community.
Aggressive, accelerated growth model with two innovative and proprietary pathways to market.